Table 1.

Study Plan

	Screening	Baseline	R3	Treatment										Follow-Up
Visits	V0	V1		V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	final visit4
Week		Week 0		Week 1					Week 2					Week 3	Week 10	Week 26/PTV
Day		- 11 to -9		1	2	3	4	5	8	9	10	11	12	17 – 19	66–68	180 – 182
Rating Scales (THI)	X1	X2						X					X	X	X	X
Otologic examination and audiological assessment	X1													X
Informed Consent	X
Demographic Data	X
Medical History	X
Documentation of Comorbidity	X	X
Documentation of concomitant medication	X	X											X	X	X	X
Physical examination		X											X			X
Vital Signs		X		X									X			X
Rating Scales (Goebel&Hiller, BDI, SF 12)		X2						X					X	X	X	X
Tinnitus-Severity		X		X				X					X	X	X	X
NEO FFI, RS-11		X
CGI		X		X				X					X	X	X	X
Neuropsychological Assessment		X											X
Cortical Excitability (pTMS)		X											X
Structural Neuroimaging (VBM)		X											X
Inclusion/Exclusion		X
Randomization			X
rTMS Treatment				X	X	X	X	X	X	X	X	X	X
Documentation of Adverse Events				X	X	X	X	X	X	X	X	X	X

¹ = results of routine clinical investigations

² = each patient receives at V1 two versions of THI and TQ to be completed on Monday and Friday before V2

³ = randomisation

⁴ = Visit 14 or PTV = Premature Termination Visit